

MEDIA RELEASE

Cordlife launches new diagnostic laboratory in Kolkata

- The new diagnostic laboratory will serve as a testing hub for Cordlife India.
- Cordlife India will use a patient-centric approach to create value-added services that will provide patients with a 360-degree view of their health status.
- The launch is consistent with the Group's goal of expanding its diagnostics business segment and its multi-layered 1-2-4 strategy for existing clients.

SINGAPORE, 9 October 2023 – Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), a Singapore Exchange mainboard listed company, is pleased to announce that its India subsidiary Cordlife Sciences India Pvt Ltd (“**Cordlife India**” or the “**Company**”) has launched their first-of-its-kind diagnostic laboratory in the heart of Kolkata, India. This facility is poised to serve as a testing hub for Cordlife India, catering to the healthcare needs of the Company's existing stem cell banking clients and their families, as well as nearby patients, healthcare partners, and physicians.

Moving a step ahead from its flagship service, stem cell banking, for securing a child's future health, Cordlife India will extend its continuum of care to more than 300,000 parents and their families who have stored their child's cord blood with the Company over the last decade. With its headquarters in Kolkata, Cordlife India will cater to their clients residing in various cities across India.

Taking a patient-centric approach, Cordlife India will provide value-added services such as personalised smart reports indicating probable risk factors, custom diet charts, and free consultations from doctors for patients. Their service includes a range of preventive packages and routine and speciality tests that will help people get a 360-degree view of their health status.

The launch of the new diagnostic service in India represents a significant leap forward in achieving Cordlife's mission of providing reliable healthcare solutions through innovation, technological advancement and commitment to quality. The Group envisions an era where early disease detection becomes a routine part of healthcare, resulting in improved quality of life and reduced healthcare costs. In celebration of the launch, Cordlife India provided free blood tests to underprivileged children at a nearby orphanage.

“Cordlife India is committed to enhancing the well-being of our existing clients, their families, and the broader community in India by providing convenient access to advanced diagnostic testing and health screenings,” said Mr Amit Srivastava, CEO of Cordlife India. “Through our patient-centric



approach, we aspire to empower individuals to take proactive steps towards their health and wellness.”

“With the launch of this new diagnostic laboratory in India, the Group has taken yet another significant step towards expanding its diagnostics business segment,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife Group Limited. “We have been working on implementing a multi-layered 1-2-4 strategy for our existing clients, with 1 representing the child, 2 representing the parents, and 4 representing the grandparents, to give them more value by expanding our scope of offerings to include more healthcare services that will help them live healthier, happier, and longer.”

End

ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia, and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue and lenticule banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening.

Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. All of the Group’s facilities are accredited by the Association for the Advancement of Blood and Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare



solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ABOUT CORDLIFE INDIA

Cordlife India (“Cordlife India” or the “Company”) is a fully owned subsidiary of Cordlife Group Limited, and it operates the most advanced umbilical cord and cord blood processing, testing, and cryopreservation facility in the country, with a storage capacity of 200,000 cord blood units that can be expanded by another several hundred thousand units. Their AABB and CAP-accredited, state-of-the-art laboratory is equipped with the latest and most advanced equipment for stem cell banking. Its facility is outfitted with a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Located within a natural calamity-proof building, their facility is also equipped with a continuous power supply and a surveillance system that operates around the clock. Cordlife is one of the largest stem cell banking companies in India, with operations in more than 200 cities.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Kamal Samuel
Ms Urvija Diwan

OFFICE : (65) 9272 1071

EMAIL : kamal@financialpr.com.sg
: urvija@financialpr.com.sg